||WO||WO/2014/045263 - PROCESS FOR PREPARATION OF INTERMEDIATES OF TELAPREVIR||27.03.2014||
||PCT/IB2013/058808||DR. REDDY'S LABORATORIES LIMITED||IQBAL, Javed|
The present application relates to novel processes for preparation of (1S,3a R,6a S)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid and its derivatives; and their use in preparation of Telaprevir.
||WO||WO/2014/041487 - ENZALUTAMIDE POLYMORPHIC FORMS AND ITS PREPARATION||20.03.2014||
||PCT/IB2013/058455||DR. REDDY'S LABORATORIES LIMITED||PEDDY, Vishweshwar|
The present application relates to crystalline and amorphous forms of Enzalutamide. The present application further relates to amorphous solid dispersions of Enzalutamide with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of Form R1 of Enzalutamide.
||WO||WO/2013/153497 - SINGLE STEP FRACTIONATION METHOD||17.10.2013||
||PCT/IB2013/052785||DR. REDDY'S LABORATORIES LIMITED||PATRA, Ashish K|
Single step method of enriching highly sialylated variant/s of a protein by use of a strong ion exchange chromatography support and a p H gradient in absence of any salt gradient.
||WO||WO/2013/150495 - PREPARATION OF TICAGRELOR||10.10.2013||
||PCT/IB2013/052733||DR. REDDY'S LABORATORIES LIMITED||DAHANUKAR, Vilas Hareshwar|
Provided are processes for preparing Ticagrelor and its intermediates that are useful in the processes. Also provided are salts of Ticagrelor, their processes and solid dispersion of Ticagrelor having Ticagrelor in amorphous form.
||WO||WO/2013/144857 - IMPROVED PROCESS FOR PRODUCING (S)-EQUOL||03.10.2013||
||PCT/IB2013/052428||DR. REDDY'S LABORATORIES LIMITED||DAHANUKAR, Vilas Hareshwar|
The present application relates to an improved process for the preparation of (S)- equol (1). The present application also relates to novel intermediates of formula (7), (7A), (8) and (9) and their use for the synthesis of (S)-equol.
||WO||WO/2013/144903 - PROCESSES FOR THE PREPARATION OF DABIGATRAN ETEXILATE||03.10.2013||
||PCT/IB2013/052500||DR. REDDY'S LABORATORIES LIMITED||DAHANUKAR, Vilas Hareshwar|
The present application relates to processes for preparing Dabigatran etexilate, including pharmaceutically acceptable salts or tautomers thereof.
||WO||WO/2013/128419 - PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS||06.09.2013||
||PCT/IB2013/051644||DR. REDDY'S LABORATORIES LIMITED||VAYA, Navin|
A pharmaceutical composition and preparing processes thereof. The composition comprises bortezomib or pharmaceutically acceptable salt or solvate thereof, tromethamine and an organic carboxylic acid, and the pH of the composition is from about 3.0 to 6.0.
||WO||WO/2013/128379 - CRYSTALLINE POLYMORPHIC FORMS OF LINAGLIPTIN||06.09.2013||
||PCT/IB2013/051556||DR. REDDY'S LABORATORIES LIMITED||RAMAKRISHNAN, Srividya|
The present application relates to crystalline polymorphs of linagliptin and to methods for their preparation. Further the present application relates to the use of the linagliptin novel polymorphs for the preparation of a medicament, and pharmaceutical compositions comprising an effective amount of the crystalline linagliptin polymorphs.
||WO||WO/2013/114165 - PROCESS OF OBTAINING GLYCOPROTEIN COMPOSITION WITH INCREASED AFUCOSYLATION CONTENT||08.08.2013||
||PCT/IB2012/057091||DR REDDY'S LABORATORIES LIMITED||MAKKAPATI, Satakarni|
The invention describes a cell culture process for obtaining a glycoprotein with the enhanced afucosylation content. The method involves culturing cells in a medium supplemented with galactose, at a specific osmolality, and harvesting on about 12th day or at about 50% viability to obtain glycoform composition with enhanced afucosylation.
||WO||WO/2013/114245 - PROCESS OF MODULATING MAN5 AND/OR AFUCOSYLATION CONTENT OF GLYCOPROTEIN COMPOSITION||08.08.2013||
||PCT/IB2013/050485||DR. REDDY'S LABORATORIES LIMITED||THUDUPPATHY, Guruvasuthevan Ramasamy|
Provided is a method for producing glycoprotein composition with an increased percentage of Man5 and/or afucosylated glycans. Use of manganese for increasing the percentage of Man5 and afucosylated glycans in glycoprotein composition is further provided.